Eisai and Biogen Advance LEQEMBI Access in Canada
TOKYO and CAMBRIDGE, Mass., August 31, 2026 Eisai and Biogen announced that Canada’s Drug Agency (CDA-AMC) has issued a...
Biogen
Advertisement
Eisai and Biogen Launch LEQEMBI IQLIK for Alzheimer’s
Tokyo, Japan and Cambridge, Massachusetts, August 25, 2026 Eisai Co., Ltd. and Biogen Inc. announced that LEQEMBI IQLIK® (lecanemab-irmb)...
Biogen Shares Positive Alzheimer’s Trial Results
CAMBRIDGE, Mass., July 14, 2026 Biogen announced positive Phase 2 CELIA study results demonstrating that investigational antisense oligonucleotide therapy...
Eisai Advances Alzheimer’s Care with LEQEMBI IQLIK Approval
TOKYO, Japan & CAMBRIDGE, Mass., July 13, 2026 Eisai Co., Ltd. and Biogen Inc. have achieved a major regulatory...
GSK and Spero Secure FDA Nod for First Oral Carbapenem
LONDON, United Kingdom, June 18, 2026 GSK plc and Spero Therapeutics have achieved a major milestone in the fight...
Advertisements
Biogen Signs Landmark RayThera Acquisition Worth Up to $1 Billion
CAMBRIDGE, Mass. and SAN DIEGO, June 17, 2026 Biogen Inc. has announced a strategic agreement to acquire RayThera Inc....
Biogen Highlights Kidney Disease Data at ERA and ATC 2026
CAMBRIDGE, Mass., June 3, 2026 Biogen Inc. announced that 14 abstracts from its expanding nephrology portfolio have been accepted...
Biogen, Denali End BIIB122 Parkinson’s Program
CAMBRIDGE, Massachusetts and SOUTH SAN FRANCISCO, California, May 21, 2026 Biogen Inc. and Denali Therapeutics Inc. announced that the...
Biogen Reports Breakthrough Tau Therapy Alzheimer Data
CAMBRIDGE, Mass., May 14, 2026 Biogen Inc. has announced promising topline results from its Phase 2 CELIA study evaluating...
Eisai and Biogen Receive FDA Extension for LEQEMBI
TOKYO and CAMBRIDGE, Mass., May 8, 2026 Eisai Co., Ltd. and Biogen Inc. announced that the U.S. Food and...
Advertisement
